CAS 558447-26-0|AMD-070
| Common Name | AMD-070 | ||
|---|---|---|---|
| CAS Number | 558447-26-0 | Molecular Weight | 349.473 |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 597.0±50.0 °C at 760 mmHg |
| Molecular Formula | C21H27N5 | Melting Point | 108-110ºC |
| MSDS | / | Flash Point | 314.9±30.1 °C |
Names
| Name | (S)-N1-((1H-Benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine |
|---|---|
| Synonym | More Synonyms |
AMD-070 BiologicalActivity
| Description | AMD-070 is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>HIVResearch Areas >>Infection |
| Target | 125I-SDF-CXCR4:13 nM (IC50) HIV-1 (NL4.3 strain):1 nM (IC50, in MT-4 cells) HIV-1 (NL4.3 strain):9 nM (IC50, in PBMCs) HIV-1 (NL4.3 strain):3 nM (IC90, in MT-4 cells) HIV-1 (NL4.3 strain):26 nM (IC90, in PBMCs) |
| In Vitro | AMD-070 is a potent and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. AMD-070 shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)[1]. AMD-070 (6.6 µM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells[2]. |
| In Vivo | AMD-070 (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss[2]. |
| Cell Assay | Cells are seeded on a 96-well plate at 5 × 103 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 µM AMD3100 or 6.6 µM AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT[2]. |
| Animal Admin | Mice[2] BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 106). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of AMD-070 (2 mg/kg)[2]. |
| References | [1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88. [2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. [3]. Chow LN, et al. Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. PLoS One. 2016 Mar 21;11(3):e0151765. |
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 597.0±50.0 °C at 760 mmHg |
| Melting Point | 108-110ºC |
| Molecular Formula | C21H27N5 |
| Molecular Weight | 349.473 |
| Flash Point | 314.9±30.1 °C |
| Exact Mass | 349.226654 |
| PSA | 70.83000 |
| LogP | 2.78 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.656 |
| InChIKey | WVLHHLRVNDMIAR-IBGZPJMESA-N |
| SMILES | NCCCCN(Cc1nc2ccccc2[nH]1)C1CCCc2cccnc21 |
Safety Information
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Synonyms
| 1,4-Butanediamine, N-(1H-benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]- |
| N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine |
| N-(1H-Benzimidazol-2-ylmethyl)-N-[(8S)-5,6,7,8-tetrahydro-8-quinolinyl]-1,4-butanediamine |
| AMD-070 |
